![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FGA |
Gene summary for FGA |
![]() |
Gene information | Species | Human | Gene symbol | FGA | Gene ID | 2243 |
Gene name | fibrinogen alpha chain | |
Gene Alias | Fib2 | |
Cytomap | 4q31.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P02671 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2243 | FGA | NAFLD1 | Human | Liver | NAFLD | 1.94e-07 | 8.24e-01 | -0.04 |
2243 | FGA | S41 | Human | Liver | Cirrhotic | 1.88e-06 | 7.12e-01 | -0.0343 |
2243 | FGA | S43 | Human | Liver | Cirrhotic | 6.34e-40 | 1.12e+00 | -0.0187 |
2243 | FGA | S44 | Human | Liver | HCC | 3.17e-08 | 1.14e+00 | -0.0083 |
2243 | FGA | HCC1_Meng | Human | Liver | HCC | 1.24e-62 | 1.94e-01 | 0.0246 |
2243 | FGA | HCC2_Meng | Human | Liver | HCC | 2.02e-25 | -8.38e-01 | 0.0107 |
2243 | FGA | cirrhotic1 | Human | Liver | Cirrhotic | 4.26e-22 | 2.99e-02 | 0.0202 |
2243 | FGA | cirrhotic2 | Human | Liver | Cirrhotic | 2.01e-22 | 2.88e-01 | 0.0201 |
2243 | FGA | cirrhotic3 | Human | Liver | Cirrhotic | 5.14e-06 | -2.85e-01 | 0.0215 |
2243 | FGA | p6 | Human | Liver | Cyst | 2.30e-02 | -8.55e-01 | -0.0218 |
2243 | FGA | HCC1 | Human | Liver | HCC | 4.79e-34 | 6.99e+00 | 0.5336 |
2243 | FGA | HCC2 | Human | Liver | HCC | 2.26e-37 | 8.23e+00 | 0.5341 |
2243 | FGA | Pt13.a | Human | Liver | HCC | 3.56e-41 | 6.22e-01 | 0.021 |
2243 | FGA | Pt13.b | Human | Liver | HCC | 1.35e-85 | 5.86e-01 | 0.0251 |
2243 | FGA | Pt13.c | Human | Liver | HCC | 2.13e-46 | 1.06e+00 | 0.0076 |
2243 | FGA | Pt14.a | Human | Liver | HCC | 2.68e-11 | 6.82e-01 | 0.0169 |
2243 | FGA | Pt14.b | Human | Liver | HCC | 4.09e-19 | 5.67e-01 | 0.018 |
2243 | FGA | Pt14.c | Human | Liver | HCC | 3.89e-02 | 4.04e-01 | 0.0054 |
2243 | FGA | Pt14.d | Human | Liver | HCC | 1.11e-21 | 6.00e-01 | 0.0143 |
2243 | FGA | S027 | Human | Liver | HCC | 7.69e-20 | 4.19e+00 | 0.2446 |
Page: 1 2 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048193 | Colorectum | AD | Golgi vesicle transport | 109/3918 | 296/18723 | 1.80e-10 | 1.68e-08 | 109 |
GO:0051656 | Colorectum | AD | establishment of organelle localization | 131/3918 | 390/18723 | 3.00e-09 | 2.06e-07 | 131 |
GO:0006900 | Colorectum | AD | vesicle budding from membrane | 32/3918 | 61/18723 | 5.38e-08 | 2.81e-06 | 32 |
GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
GO:0051650 | Colorectum | AD | establishment of vesicle localization | 57/3918 | 161/18723 | 1.47e-05 | 3.15e-04 | 57 |
GO:0051648 | Colorectum | AD | vesicle localization | 59/3918 | 177/18723 | 7.83e-05 | 1.25e-03 | 59 |
GO:0009306 | Colorectum | AD | protein secretion | 105/3918 | 359/18723 | 1.05e-04 | 1.57e-03 | 105 |
GO:0035592 | Colorectum | AD | establishment of protein localization to extracellular region | 105/3918 | 360/18723 | 1.18e-04 | 1.73e-03 | 105 |
GO:0071692 | Colorectum | AD | protein localization to extracellular region | 106/3918 | 368/18723 | 1.86e-04 | 2.49e-03 | 106 |
GO:0006903 | Colorectum | AD | vesicle targeting | 19/3918 | 45/18723 | 9.94e-04 | 9.28e-03 | 19 |
GO:0048194 | Colorectum | AD | Golgi vesicle budding | 7/3918 | 10/18723 | 1.15e-03 | 1.04e-02 | 7 |
GO:0006901 | Colorectum | AD | vesicle coating | 9/3918 | 17/18723 | 3.57e-03 | 2.57e-02 | 9 |
GO:00516561 | Colorectum | SER | establishment of organelle localization | 100/2897 | 390/18723 | 1.11e-07 | 6.79e-06 | 100 |
GO:00481931 | Colorectum | SER | Golgi vesicle transport | 79/2897 | 296/18723 | 4.20e-07 | 2.15e-05 | 79 |
GO:00069001 | Colorectum | SER | vesicle budding from membrane | 23/2897 | 61/18723 | 1.95e-05 | 5.66e-04 | 23 |
GO:00516501 | Colorectum | SER | establishment of vesicle localization | 42/2897 | 161/18723 | 3.38e-04 | 5.35e-03 | 42 |
GO:00160501 | Colorectum | SER | vesicle organization | 69/2897 | 300/18723 | 3.59e-04 | 5.61e-03 | 69 |
GO:00093061 | Colorectum | SER | protein secretion | 79/2897 | 359/18723 | 5.99e-04 | 8.19e-03 | 79 |
GO:00355921 | Colorectum | SER | establishment of protein localization to extracellular region | 79/2897 | 360/18723 | 6.54e-04 | 8.77e-03 | 79 |
GO:00716921 | Colorectum | SER | protein localization to extracellular region | 80/2897 | 368/18723 | 8.13e-04 | 1.01e-02 | 80 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0517162 | Liver | Cyst | Coronavirus disease - COVID-19 | 75/339 | 232/8465 | 2.97e-49 | 4.27e-47 | 3.53e-47 | 75 |
hsa0517172 | Liver | Cyst | Coronavirus disease - COVID-19 | 75/339 | 232/8465 | 2.97e-49 | 4.27e-47 | 3.53e-47 | 75 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FGA | SNV | Missense_Mutation | rs762511080 | c.2059N>T | p.Arg687Trp | p.R687W | P02671 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AF-A56L-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
FGA | SNV | Missense_Mutation | c.1171G>A | p.Gly391Arg | p.G391R | P02671 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.737) | TCGA-AG-3592-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FGA | SNV | Missense_Mutation | c.2570G>A | p.Arg857His | p.R857H | P02671 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
FGA | SNV | Missense_Mutation | rs750761333 | c.428G>A | p.Arg143His | p.R143H | P02671 | protein_coding | tolerated(0.06) | probably_damaging(0.952) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
FGA | SNV | Missense_Mutation | rs755603154 | c.1561G>A | p.Asp521Asn | p.D521N | P02671 | protein_coding | tolerated(0.14) | benign(0.01) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FGA | SNV | Missense_Mutation | c.305C>A | p.Ser102Tyr | p.S102Y | P02671 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
FGA | insertion | In_Frame_Ins | novel | c.373_374insCTTACCTCCAGTCGTTTC | p.Asn125delinsThrTyrLeuGlnSerPheHis | p.N125delinsTYLQSFH | P02671 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
FGA | insertion | Frame_Shift_Ins | rs757027534 | c.1978dupT | p.Ser660PhefsTer27 | p.S660Ffs*27 | P02671 | protein_coding | TCGA-CK-4950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folfox | SD | ||
FGA | SNV | Missense_Mutation | novel | c.162C>A | p.Phe54Leu | p.F54L | P02671 | protein_coding | tolerated(0.08) | possibly_damaging(0.553) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGA | SNV | Missense_Mutation | novel | c.1885G>A | p.Val629Ile | p.V629I | P02671 | protein_coding | tolerated(0.05) | benign(0.012) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | RETEPLASE | RETEPLASE | ||
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | RECOMBINANT FACTOR IX FC FUSION PROTEIN | |||
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | ALFIMEPRASE | ALFIMEPRASE | ||
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | ANISTREPLASE | ANISTREPLASE | ||
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | inhibitor | CHEMBL1201505 | FIBRINOLYSIN, HUMAN | |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | eptifibatide | EPTIFIBATIDE | 20938371 | |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | tirofiban | TIROFIBAN | 20938371 | |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | abciximab | ABCIXIMAB | 20938371 | |
2243 | FGA | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, FIBRINOGEN | ALTEPLASE | ALTEPLASE |
Page: 1 |